1. Home
  2. ELVA vs ALT Comparison

ELVA vs ALT Comparison

Compare ELVA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Electrovaya Inc.

ELVA

Electrovaya Inc.

HOLD

Current Price

$10.34

Market Cap

466.7M

Sector

N/A

ML Signal

HOLD

Logo Altimmune Inc.

ALT

Altimmune Inc.

HOLD

Current Price

$2.71

Market Cap

421.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELVA
ALT
Founded
1996
1997
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
466.7M
421.5M
IPO Year
2021
2005

Fundamental Metrics

Financial Performance
Metric
ELVA
ALT
Price
$10.34
$2.71
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$14.00
$17.67
AVG Volume (30 Days)
526.4K
2.6M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.37
EPS
N/A
N/A
Revenue
N/A
$41,000.00
Revenue This Year
$34.68
N/A
Revenue Next Year
$51.48
N/A
P/E Ratio
$78.51
N/A
Revenue Growth
N/A
105.00
52 Week Low
$3.11
$2.56
52 Week High
$12.78
$7.73

Technical Indicators

Market Signals
Indicator
ELVA
ALT
Relative Strength Index (RSI) 47.95 37.23
Support Level $8.51 $2.56
Resistance Level $11.41 $3.20
Average True Range (ATR) 0.80 0.13
MACD -0.08 -0.00
Stochastic Oscillator 38.72 2.25

Price Performance

Historical Comparison
ELVA
ALT

About ELVA Electrovaya Inc.

Electrovaya Inc is a technology-focused lithium-ion battery company engaged in designing, developing and manufacturing battery cells, modules and systems based on its proprietary Infinity Battery Technology, which provides high safety performance, long cycle life and durability. The Company supplies low-voltage and high-voltage battery systems for industrial and transportation markets, including material-handling equipment, robotic vehicles, electric buses and trucks, and energy-storage installations, and its products are suitable for mission-critical applications. it maintains an expanding intellectual-property portfolio, develops next-generation solid-state and hybrid solid-state battery technologies, and sells its products through OEM relationships, dealer networks and direct sales.

About ALT Altimmune Inc.

Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Share on Social Networks: